Attorneys: Scientific free speech 'threatened'

Share this article:

Attorneys Arnold Friede and Robert Nicholas (both McDermott, Will & Emery) say calls for an investigation into support for the American Heart Association (AHA) and American College of Cardiology are likely to convince other scientific groups not to speak out on issues of public concern. The two groups were criticized for issuing statements on the results of the controversial Vytorin ENHANCE study.

Writing in a Washington Legal Foundation Legal Backgrounder, Friede and Nicholas say the statements issued by the groups did little more than to advise patients to consult doctors before stopping taking Vytorin.

However, the House Energy and Commerce Committee reportedly plans to send letters to the two groups opening an investigation into their relationships with drug manufacturers because their statements did not disclose the company financial support they receive.

The attorneys say no one can question the status of the AHA and American College of Cardiology as scientific speakers in the debate about some of the most important public health issues of our time, even if they receive some financial support from commercial interests. 
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?